Replimune Group, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Replimune Group, Inc. now
Current reporting with the operating signal separated from the noise.
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
The story matters when it changes Replimune Group, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm
Investors are testing whether Replimune Group, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
Investors are testing whether Replimune Group, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The story matters when it changes Replimune Group, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest REPL filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Replimune Group, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →